<DOC>
	<DOCNO>NCT02418624</DOCNO>
	<brief_summary>A phase I trial determine recommend phase two dose combination carboplatin olaparib .</brief_summary>
	<brief_title>Phase I Carboplatin-Olaparib Followed Olaparib Monotherapy Advanced Cancer</brief_title>
	<detailed_description>A 3+3 dose escalation trial 2 cycle ( 21 day ) carboplatin olaparib combination therapy , follow olaparib monotherapy progression unacceptable toxicity patient advanced cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Inclusion criterion : 1 . Histological cytological proof advance cancer pretreated maximally one line systemic chemotherapy advance set line hormonal therapy advance disease , potentially benefit olaparibcarboplatin combination therapy ( prior ( neo ) adjuvant chemotherapy accept count one line , since administer early stage disease ) ; 2 . Age ≥ 18 year ; 3 . Able willing give write informed consent ; 4. WHO performance status 0 , 1 2 ; 5 . Able willing undergo blood sample PK PD analysis ; 6 . Life expectancy ≥ 3 month , allow adequate follow toxicity evaluation antitumor activity ; 7 . Evaluable disease accord RECIST 1.1 criterion ; 8 . Minimal acceptable safety laboratory value 1 . ANC ≥ 1.5 x 10^9 /L 2 . Hemoglobin least 6.2 mM transfusion last 28 day . 3 . Platelet count ≥ 100 x 10^9 /L 4 . Hepatic function define serum bilirubin ≤ 1.5 x ULN ( &lt; 3 x ULN case know Gilbert syndrome ) , ASAT ALAT 2.5 x ULN ( &lt; 5 x ULN case liver metastasis ) 5 . Renal function define serum creatinine ≤1.5 x ULN creatinine clearance ≥ 50 mL/min ( CockcroftGault formula ) ; 9 . Negative pregnancy test ( urine/serum ) female patient childbearing potential ; Exclusion criteria 1 . Any treatment investigational drug within 28 day prior receive first dose investigational treatment ; 21 day standard ( neo ) adjuvant chemotherapy , hormonal immunotherapy ; 2 . Patients receive high dose alkylating agent , PARP1 inhibitor carboplatin pretreatment ; unless progression carboplatin observe earlier treatment last carboplatin administration longer 6 month ago ; 3 . Any current treatment drug induce inhibit CYP3A4 system : http : //www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm # inVivo APPENDIX IX 4 . Women positive pregnancy test ( urine/serum ) and/or breast feeding ; 5 . Unreliable contraceptive method . Women men enrol trial must agree use reliable contraceptive method throughout study ( adequate contraceptive method : oral , injected implant hormonal method , intrauterine device system , condom barrier contraceptive measure , sterilization true abstinence ) 6 . Radiotherapy within last four week prior receive first dose investigational treatment ; except 1x8 Gy pain palliation seven day interval maintain ; 7 . Uncontrolled infectious disease know Human Immunodeficiency Virus HIV1 HIV2 type patient ; 8 . Patients know active hepatitis B C ; 9 . Recent myocardial infarction ( &lt; six month ) unstable angina ; 10 . Symptomatic brain metastasis . If adequately treat resection and/or irradiation patient least four week completely free symptom metastasis without medication relate metastasis patient could eligible exclusion criterion obey . 11 . Known leptomeningeal metastasis . 12 . Patients myelodysplastic syndrome acute myeloid leukemia 13 . Any medical condition yet specify consider possibly , probably definitely interfere study procedure , include adequate followup compliance and/or would jeopardize safe treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>breast cancer 1 , early onset ( BRCA1 )</keyword>
	<keyword>breast cancer 2 , early onset ( BRCA2 )</keyword>
	<keyword>homologous recombination deficiency</keyword>
	<keyword>carboplatin</keyword>
	<keyword>olaparib</keyword>
</DOC>